Diego Thomazini
GlaxoSmithKline (NYSE:GSK) and Sanofi (NASDAQ:SNY) had been the 2 greatest performing giant cap European pharmaceutical corporations in October as each returned ~10%.
GSK (GSK) was buoyed within the month by robust part 3 efficacy outcomes for its respiratory syncytial virus (RSV) vaccine candidate.
The European Medicines Company and Japanese regulators accepted functions for the candidate later within the month. Extra world regulatory filings for the candidate are anticipated by the tip of the yr.
The British pharma was additionally helped by a US FDA advisory panel’s overwhelming vote in favor of aprodustat for anemia attributable to power kidney illness.
Take a look at In search of Alpha’s contributor John Kingham’s evaluation of GSK (GSK) from a dividend investor’s perspective.
Sanofi’s (SNY) robust October displaying was tremendously impacted by its strong Q3 2022 monetary outcomes, which not solely beat on the highest and backside strains, but in addition led to the corporate’s elevating its full-year steering.
Within the month, Sanofi additionally launched constructive part 3 information on Dupixent (dupilumab) for kids with eosinophilic esophagitis.
In search of Alpha’s Quant Ranking views Sanofi (SNY) as a maintain with excessive marks for profitability and revisions.
Novo Nordisk (NVO) was the third greatest performer of the month with a ~6.3% return.
The spotlight for the corporate got here early within the month with part 3 information displaying that its insulin icodec bested once-daily basal insulin when it comes to decreasing A1c. Novo (NVO) expects to use for approval with regulators within the US, EU, and China in 1H 2023.
Learn why In search of Alpha contributor Daniel Schonberger says that Novo (NVO) is a maintain as a result of the inventory is expensive.
AstraZeneca (NASDAQ:AZN) was the fourth greatest performer with a 5.7% return.
Maybe the largest growth for the UK pharma within the month was the approval of Imjudo (tremelimumab) together with Imfinzi (durvalumab) to deal with grownup sufferers with unresectable hepatocellular carcinoma.
Later within the month, part 2 information on camizestrant confirmed survival profit in comparison with Faslodex (fulvestrant) in sure breast most cancers sufferers.
Take a look at In search of Alpha contributor’s Keith Williams’ deep dive on investing in AstraZeneca (AZN).
The worst performer of the month was BioNTech (NASDAQ:BNTX), which eked out a small acquire of 0.8%.
BioNTech (BNTX) was damage within the month by stories that uptake within the US of the replace COVID-19 booster photographs has been weak.
The German biotech will launch Q3 2022 earnings on Monday earlier than the closing bell, and the consensus EPS and income estimates mirror huge declines from the year-ago interval.
In search of Alpha’s Quant Ranking views BioNTech (BNTX) as a maintain with excessive marks for valuation, progress, and profitability.
